EPA:GNFT Genfit (GNFT) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free GNFT Stock Alerts €3.24 +0.07 (+2.21%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range€3.16▼€3.2550-Day Range€3.14▼€3.5852-Week Range N/AVolume49,417 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesStock AnalysisChartHeadlines Get Genfit alerts: Email Address Ad Behind the MarketsPentagon contract could send this $2 AI stock soaringWhenever the Department of Defense awards a major AI contract... Early investors could see dramatic returns virtually overnight. That's how my readers were able to cash in gains like 133% in just four months on C3.ai...Get all the info here >>> About Genfit Stock (EPA:GNFT)Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.Read More GNFT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GNFT Stock News HeadlinesApril 8, 2024 | markets.businessinsider.comBuy Rating Reiterated for Genfit SA Amidst Promising Clinical Developments and Strong Financial OutlookApril 5, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Close Out Week LowerApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 5, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Genfit SA (GNFT) and Laboratory (LH)February 15, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday TradingFebruary 14, 2024 | markets.businessinsider.comGenfit (GNFTF) Gets a Buy from Kepler CapitalJanuary 20, 2024 | finance.yahoo.comGenfit S.A. (GNFT.PA)January 15, 2024 | finance.yahoo.comGENFIT Announces 2024 Financial CalendarApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.December 11, 2023 | markets.businessinsider.comBuy Rating Affirmed for Genfit SA Amid Favorable Regulatory Developments and Positive Trial ResultsDecember 6, 2023 | finance.yahoo.comGENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical TrialsNovember 16, 2023 | finance.yahoo.comGENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023November 13, 2023 | msn.comGenfit stock rallies 20% after hours on data for liver disease drugNovember 12, 2023 | markets.businessinsider.comKepler Capital Sticks to Its Buy Rating for Genfit (GNFTF)November 10, 2023 | finanznachrichten.deGENFIT S.A.: GENFIT Reports Third Quarter 2023 Financial InformationNovember 2, 2023 | finance.yahoo.comGENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023November 1, 2023 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Rise in Wednesday TradingAugust 14, 2023 | msn.comUBS starts Cymabay at buy, expecting positive Phase 3 data for seladelparAugust 11, 2023 | finance.yahoo.comGENFIT Announces the Publication of New Data on the Clinical Performance of NIS2+™ in Older Patients in Hepatology CommunicationsJuly 3, 2023 | markets.businessinsider.comAnalyst Expectations for Genfit's FutureJune 30, 2023 | msn.comGenfit gains as Phase 3 trial for liver disease candidate succeeds (update)June 30, 2023 | markets.businessinsider.comIpsen, GENFIT Reveal Positive Phase III Trial Results Of Elafibranor In Patients With PBCJune 4, 2023 | msn.comGenfit (EPA:GNFT) Price Target Decreased by 11.94% to 8.02May 24, 2023 | finance.yahoo.comGENFIT: May 24, 2023 Combined Shareholders Meeting resultsMay 12, 2023 | finanznachrichten.deGENFIT S.A.: GENFIT Reports First Quarter 2023 Financial InformationMay 11, 2023 | msn.comGenfit: Major Data Release Before End Of Q2 Of 2023 Could Get Ball RollingMay 11, 2023 | finance.yahoo.comGENFIT Reports First Quarter 2023 Financial InformationSee More Headlines Receive GNFT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genfit and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeEPA SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolEPA:GNFT CUSIPN/A CIKN/A Webwww.genfit.com Phone33 3 20 16 40 00FaxN/AEmployees159Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Jean-Francois Mouney (Age 69)Co-Founder & Chairman of the Board Comp: $359.01kMr. M. Pascal Prigent (Age 55)Chief Executive Officer Comp: $557.66kProf. Bart Staels (Age 61)Co-Founder & Chairman of the Scientific Advisory Board Mr. Thomas Baetz (Age 49)Chief Financial Officer Mr. Pascal Caisey (Age 55)Chief Operating Officer Dr. Meriam Kabbaj Ph.D. (Age 50)Chief Technology Officer Dr. Dean W. Hum Ph.D. (Age 62)Chief Scientific Officer Comp: $710.72kMr. Jean-Christophe Marcoux (Age 46)Chief Corporate Affairs Officer, Head of Investor Relations & Head of ESG Mr. Laurent Lannoo (Age 53)Corporate Secretary & Director of Legal Affairs Ms. Stefanie Magner J.D. (Age 42)Chief Compliance Officer & Executive VP of International Legal Affairs More ExecutivesKey CompetitorsEssilor International Société AnonymeEPA:EIFielmann GroupFRA:FIEFresenius SE & Co. KGaAFRA:FRESanofiEPA:SANSartorius AktiengesellschaftFRA:SRT3View All Competitors GNFT Stock Analysis - Frequently Asked Questions How have GNFT shares performed in 2024? Genfit's stock was trading at €3.54 on January 1st, 2024. Since then, GNFT stock has decreased by 8.6% and is now trading at €3.24. View the best growth stocks for 2024 here. What other stocks do shareholders of Genfit own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genfit investors own include Alimentation Couche-Tard (ATD.B), Aecon Group (ARE), Algonquin Power & Utilities (AQN), Aptiv (APTV), American Tower (AMT), Advanced Micro Devices (AMD), Ambarella (AMBA), Albemarle (ALB), Adobe (ADBE) and Abbott Laboratories (ABT). This page (EPA:GNFT) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersIs Tesla going out of business?DTIMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genfit S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
